This article looks at the value of outsourcing research and development capabilities.
By Andrew Smith, Institute of Clinical Research
New EU legislation will soon impact the generic drug industries of the new member states ? and potentially their healthcare systems.
The pharmaceutical industry is on the cusp of an adapt-or-die stage in its evolution ? but the latest generation of IT support tools are proving invaluable as it tackles the spiralling costs and regulatory demands associated with clinical trials.
NGP speaks to Deb Brewer, Vice President of International Business Development and Marketing at Omnicare Clinical
Research